Literature DB >> 7461050

Characterization of marrow stromal (fibroblastoid) cells and their association with erythropoiesis.

E D Werts, R L DeGowin, S K Knapp, D P Gibson.   

Abstract

Our previous studies suggested that a defect in the hemopoietic microenvironment of bone marrow occurred in the anemia of chronic inflammatory disease. We examined the in vivo hemopoietic and marrow stromal cell (MSC) response of shielded marrow to 5000 rad leg-irradiation (5000 rad LI), the in vitro growth of BFUE, CFUE, and CFUC in co-culture with MSC, and the in vitro characteristics of MSC. One month after 5000 rad LI, erythroblasts and MSC fell to 18% and 26% respectively. BFUE and CFUE in shielded marrow increased 1.5 to 2 times. Total CFUS and CFUC were normal. In co-culture, small numbers of MSC enhanced BFUE and CFUE, but suppressed CFUC. MSC in colonies were polygonal cells with a plating efficiency of 10 per 10(6) nucleated marrow cells and 1 per 10(6) spleen or nucleated blood cells. MSC were not phagocytic and did not stain with nonspecific esterase. We conclude that in mice with an inflammatory response to 5000 rad LI: 1) Erythroblasts and MSC decreased while erythroid progenitors (BFUE and CFUE) increased in the shielded marrow, 2) MSC stimulated BFUE and CFUE in co-culture, 3) MSC in colonies were adherent, large polygonal cells that may enhance erythroid maturation in the bone marrow.

Entities:  

Mesh:

Year:  1980        PMID: 7461050

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

Review 1.  The origins of mesenchymal stromal cell heterogeneity.

Authors:  Meirav Pevsner-Fischer; Sarit Levin; Dov Zipori
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

2.  The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.

Authors:  Robert O'Connor; Melissa G Ooi; Justine Meiller; Jana Jakubikova; Steffen Klippel; Jake Delmore; Paul Richardson; Kenneth Anderson; Martin Clynes; Constantine S Mitsiades; Peter O'Gorman
Journal:  Cancer Chemother Pharmacol       Date:  2013-04-16       Impact factor: 3.333

Review 3.  Deterministic and stochastic approaches in the clinical application of mesenchymal stromal cells (MSCs).

Authors:  Simone Pacini
Journal:  Front Cell Dev Biol       Date:  2014-09-12

4.  Are MSCs angiogenic cells? New insights on human nestin-positive bone marrow-derived multipotent cells.

Authors:  Simone Pacini; Iacopo Petrini
Journal:  Front Cell Dev Biol       Date:  2014-05-20

Review 5.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Authors:  Lisa Pleyer; Peter Valent; Richard Greil
Journal:  Int J Mol Sci       Date:  2016-06-27       Impact factor: 5.923

Review 6.  Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines.

Authors:  Wenqing Liang; Xiaozhen Chen; Songou Zhang; Jian Fang; Meikai Chen; Yifan Xu; Xuerong Chen
Journal:  Cell Mol Biol Lett       Date:  2021-01-20       Impact factor: 5.787

Review 7.  Mesenchymal stem cells in cancer therapy; the art of harnessing a foe to a friend.

Authors:  Mehdi Karimi-Shahri; Hossein Javid; Alireza Sharbaf Mashhad; Shaghayegh Yazdani; Seyed Isaac Hashemy
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.